United
Kingdom osteoporosis market is anticipated to witness impressive growth during
the forecast period. This can be ascribed to the growing demand
for diagnostic tests because it gives some benefits such as early detection and
diagnosis, accurate diagnosis, tailored treatment plans and monitoring
treatment efficacy along with growing demand for medications intake as daily
routine for bone benefits. Also, increasing demand for bisphosphonates and
hormone replacement therapy (HRT) additives along with growing demand for lifestyle
modifications and fracture prevention strategies such as calcium and vitamin D
intake, regular weight-bearing exercises, smoking cessation, alcohol moderation
and fall prevention measures, home safety assessments, and assistive devices is
expected to create a lucrative growth of United Kingdom osteoporosis market
during the forecast period.
One in five female fractured patients break three or
more bones before getting help. In UK, over 3 million are estimated to have
osteoporosis, and over 500,000 fragility fractures are estimated to happen each
year. The demand for medications to treat osteoporosis is significant. Various
types of medications are prescribed, including bisphosphonates, selective
estrogen receptor modulators (SERMs), hormone replacement therapy (HRT),
denosumab, and anabolic agents like teriparatide and abaloparatide. Advancements in diagnostic
techniques and treatment options have improved the management of osteoporosis, the
development of novel medications and therapies has expanded the United Kingdom osteoporosis
treatment market. As there are so many ongoing research and development
activities, osteoporosis researchers are exploring new drug targets and
developing innovative therapies for the treatment of osteoporosis as these may
promotes the United Kingdom osteoporosis treatment market.
Increase In Osteoporosis-Related Fractures Drives the Market
The
increase in osteoporosis-related fractures play a significant role in driving
the United Kingdom osteoporosis market. The estimated annual incidence of
fractures is 3.6 fractures per 100 individuals. Men in their middle age have a
lifetime fracture rate of over 50%, while women over 75 have a frequency of 40%.
Osteoporosis-related fractures, such as hip fractures, vertebral fractures,
and wrist fractures, often require medical intervention and long-term
treatment. Hip fracture is a serious and costly injury affecting mainly
geriatric people. There are estimated 76,000 hip fracture, occurring each year
in United Kingdom as a whole. As the number of fractures increases, there
is a corresponding rise in the demand for osteoporosis treatments, including
medications, rehabilitation services, and surgical procedures.
Osteoporosis-related fractures impose a substantial economic burden on
healthcare systems. The cost of hospitalizations, surgeries, rehabilitation,
and long-term care associated with these fractures can be substantial.
Approximately 2.4% of UK healthcare spending, or USD 5.5
billion out of USD 227.2 billion in 2019, was spent on osteoporotic fractures. This increased healthcare
expenditure drives the United Kingdom osteoporosis treatment market.
Osteoporosis-related fractures can have severe consequences, including pain,
reduced mobility, disability, and decreased quality of life. Effective
osteoporosis treatment can alleviate symptoms, improve bone density, and reduce
the risk of future fractures. As patients seek to maintain or regain their quality
of life, there is a higher demand for osteoporosis treatments market in United
Kingdom.
The
increase in osteoporosis-related fractures stimulates research and innovation
in the field of osteoporosis treatment. Pharmaceutical companies and
researchers invest in developing new medications, therapies, and technologies
to address the rising demand. It leads to advancements in treatment options and
drives the United Kingdom osteoporosis treatment market.
Increase in Sedentary Lifestyle
The
rise in sedentary lifestyles can contribute to the increase in the United
Kingdom osteoporosis treatment market. Over 80% of office goers in the UK
spend between four to nine hours per day at their desks, which equates to 67
sedentary days on an average. Annually around 1/3 (34%) of men and ½ (42%) of
women are not active enough for good health. Sedentary lifestyles,
characterized by a lack of physical activity and prolonged sitting, are
associated with an increased risk of osteoporosis. Inactivity and lack of
weight-bearing exercise can lead to decreased bone mineral density, weakening
the bones and making them more susceptible to fractures. The higher the risk of
osteoporosis, the greater the demand for osteoporosis treatment. Osteoporosis
rates increase with sedentary lifestyles across all age groups. Sedentary
lifestyles are one of the significant yet under-addressed public health issues,
with 60 to 85% of people following it worldwide, according to WHO.
The
recognition of the detrimental effects of sedentary lifestyles on bone health
and the increased risk of osteoporosis can lead to greater awareness among both
healthcare professionals and the general population. This awareness can drive
the demand for osteoporosis screening and diagnosis, as individuals become more
proactive in assessing their bone health and seeking appropriate treatment. The
rise in sedentary lifestyles prompts the development of lifestyle modification
programs aimed at promoting physical activity and reducing sedentary behavior.
These programs may include exercise regimens specifically designed to improve
bone health, promote muscle strength and balance, and reduce the risk of falls
and fractures. The demand for such programs contributes to the growth of the
United Kingdom osteoporosis treatment market.
Aging Population Adds to the Growth of Market
The
aging population plays a significant role in driving the United Kingdom
osteoporosis treatment market. Age is a significant fracture risk factor.
According to estimates, the number of people in the UK who are 50 or older will
rise by 13.2% between 2019 and 2034. Further increases may be seen amongst men
and women who are 75 years or older: 42.2% for men and 31.0% for women. As a
result, fragility fractures are expected to become more common and cause more
harm. Osteoporosis is more prevalent among older individuals, and as the
population ages, the number of people affected by osteoporosis increases. This
higher prevalence leads to a larger pool of patients in need of osteoporosis
treatment, driving the demand for treatment options in the market. Aging is a
major risk factor for osteoporosis-related fractures. As individuals grow
older, their bone density naturally decreases, making them more susceptible to
fractures.
1 out of 2 women and up to 1 out of 4 men over age 50. The aging population's
higher risk of fractures creates a greater demand for osteoporosis treatment to
reduce the risk and consequences of fractures. With advancements in healthcare
and improved quality of life, the average life expectancy in the United Kingdom
has increased. A longer life expectancy means that individuals are living
longer with osteoporosis and may require prolonged treatment and management of
the condition, leading to sustained demand for osteoporosis treatment which
grow the United Kingdom osteoporosis treatment market.
Recent Development
In 2017, UCL and Amgen announced a collaboration
focused on the discovery and development of new therapeutic targets for
musculoskeletal diseases, including osteoporosis. The collaboration aimed to
leverage UCL's expertise in musculoskeletal biology and Amgen's capabilities in
drug discovery to identify potential novel therapies.
In 2011, Novartis acquired Alcon, a multinational eye
care company. While Alcon's focus is primarily on eye care, the acquisition
expanded Novartis' presence in the healthcare market, potentially influence
their offerings in areas such as osteoporosis treatment.
In 2019, the University of Liverpool and Eli Lilly
announced a collaboration to investigate the effects of osteoporosis treatments
on cardiovascular health. The partnership aimed to improve the understanding of
the cardiovascular risks associated with osteoporosis medications and identify
potential strategies to optimize treatment outcomes.
Market Segmentation
The
United Kingdom osteoporosis treatment market can be segmented by drug class, route
of administration, application, and region. Based on drug class, the market can
be segmented into parathyroid hormone therapy,
bisphosphonates, calcitonin, RANKL inhibitors, and others. Based on route
of administration, the market can be segmented into oral, parenteral, and others.
Based on application, the market can be bifurcated into primary osteoporosis
and secondary osteoporosis. Based on region, the market can be grouped into Scotland,
South- East, London, South-West, Yorkshire & Humberside, East Midlands
Market Players
GlaxoSmithKline
Ltd, AstraZeneca Ltd, Amgen Ltd, Eli Lilly & Co, Pfizer Ltd, Novartis Ltd,
Merck & Co., UCB Pharma Ltd, Johnson & Johnson Ltd, Servier
Pharmaceuticals LLC/United Kingdom are some of the leading players operating in
the United Kingdom osteoporosis treatment market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 –
2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024
– 2028
|
|
Quantitative
Units
|
Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
Drug Class
Route of Administration
Application
|
|
Regional
scope
|
Scotland,
South-East, London, South-West, Yorkshire & Humberside and East Midlands
|
|
Key
companies profiled
|
GlaxoSmithKline Ltd, AstraZeneca Ltd, Amgen Ltd, Eli Lilly
& Co, Pfizer Ltd, Novartis Ltd, Merck & Co., UCB Pharma Ltd, Johnson
& Johnson Ltd, Servier Pharmaceuticals LLC/United Kingdom.
|
|
Customization
scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through
Email (We can also provide the editable version of the report in PPT/Word format
on special request)
|
Report
Scope:
In this
report, the United Kingdom osteoporosis treatment market has been segmented into
the following categories, in addition to the industry trends which have also
been detailed below:
- United Kingdom Osteoporosis
Treatment Market, By Drug Class:
o Parathyroid Hormone Therapy
o Bisphosphonates
o Calcitonin
o RANKL Inhibitors
o Others
- United Kingdom Osteoporosis
Treatment Market, By Route of Administration:
o Oral
o Parental
o Others
- United Kingdom Osteoporosis
Treatment Market, By Application:
o Primary Osteoporosis
o Secondary Osteoporosis
- United Kingdom Osteoporosis
Treatment Market, By Region:
o
Scotland
o
South- East
o
London
o
South-West
o
Yorkshire & Humberside
o
East Midlands
Competitive
Landscape
Company
Profiles: Detailed analysis of the major
companies present United Kingdom osteoporosis treatment market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
United
Kingdom osteoporosis treatment market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]